| | | | | |
| OMB APPROVAL |
|
| OMB Number: | | | 3235-0060 |
| Expires: | | March 31, 2006 |
| Estimated average burden | | | | |
| hours per response | | | 28.0 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 1, 2004 (November 30, 2004)
Myogen, Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
Delaware | | 000-50438 | | 84-1348020 |
| |
| |
|
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | | |
7575 West 103rd Avenue, Suite 102
Westminster, Colorado | |
80021 |
| |
|
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code:(303) 410-6666
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| |
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
INFORMATION TO BE INCLUDED IN THE REPORT
Section 8 — Other Events
Item 8.01 Other Events.
On November 30, 2004, Myogen, Inc. issued a press release announcing completion of the treatment phase of pivotal Phase III trials of enoximone in chronic heart failure. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
(c)Exhibits.
| | | |
| 99.1 | | Press Release, dated November 30, 2004, Entitled “Myogen Announces Completion of Treatment Phase of Pivotal Phase III Trials of Enoximone in Chronic Heart Failure.” |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated November 30, 2004
| | | | | |
| | MYOGEN, INC.
| |
| | By: | /s/ J. William Freytag | |
| | | J. William Freytag | |
| Its: | President and Chief Executive Officer | |
| |
EXHIBIT INDEX
| | | |
Exhibit No.
| | Description
|
| 99.1 | | Press Release, dated November 30, 2004, Entitled “Myogen Announces Completion of Treatment Phase of Pivotal Phase III Trials of Enoximone in Chronic Heart Failure.” |
